12 results about "Meninges" patented technology

This invention provides a near-infrared therapy device for improving Alzheimer's disease, characterized by comprising: a frequency-modulated drive circuit 1, a near-infrared LD light source 2, an optical fiber coupler 3, a light source power monitoring photodetector (PD) 4, an optical power monitoring circuit 5, an optical fiber beam splitter 6, an MPO optical fiber cable 7, and an optical transmitter 8. The optical transmitter includes an optical transmitter housing 8-1, a fiber-end hemispherical emitting microlens 8-2, and a beam-shaping coupling lens 8-3. This invention can be used to regulate the metabolism and cellular function of meningeal lymphatic endothelial mitochondrial cells, promote meningeal lymphatic transport in the central nervous system, thereby alleviating the pathological symptoms of Alzheimer's patients and enhancing their cognitive function. The device has a simple and compact structure, is easy to plug and unplug, has low optical signal loss, and high coupling efficiency. It can be widely used in novel non-invasive optical brain-computer interface devices and belongs to the field of fiber optic sensing technology.

This invention discloses a submillimeter-level diffusion magnetic resonance imaging (DTI) method for extracting the radial index of cortical layered cognitive structures, relating to the field of medical image processing technology. This invention aims to address the problems of existing technologies failing to accurately quantify the directionality of cortical microstructures and neglecting the heterogeneity of cortical layering. The method includes: acquiring DTI data and performing high-fidelity preprocessing such as MP-PCA denoising, Gibbs artifact removal, and Gaussian process distortion correction; estimating the diffusion tensor and extracting the principal feature vector based on the preprocessed data; reconstructing the cortical white matter and pia mater surface using T1 images and extracting the normal vector; calculating the absolute value of the dot product of the diffusion principal feature vector and the surface normal vector to construct a radial index map; and segmenting the cortex into multiple intermediate layers based on the principle of equal volume and extracting layering parameters. Through refined high-resolution data processing and geometric modeling, this invention can accurately quantify the radial alignment integrity of cortical nerve fibers, providing highly sensitive imaging markers for cognitive disorders such as schizophrenia.

A dura mater incision device for neurosurgery, wherein a rotating column (2) is provided on a movable cabinet mechanism by means of a rotary damper (1); the upper end of the rotating column (2) is provided with a connecting rocker arm (4) by means of a mounting base (3); an end portion of the connecting rocker arm (4) is provided with a connecting mechanism; the front end of a handpiece (5) is provided with a guard plate (7) by means of a hinged connecting base (6); a movable carriage (9) is provided above the guard plate (7) by means of a movable guide groove (8); the lower side of the movable carriage (9) is provided with a dural knife (10) by means of an adjusting base mechanism; and a driving mechanism is provided between the handpiece (5) and the movable carriage (9). By rotatably arranging the connecting rocker arm (4), movable support can be provided for an incision knife mechanism. This design requires only manual gripping for directional adjustment and movement, without the need to fully hand-hold the incision knife mechanism during operation, thereby relieving the surgeon from the gravitational load of the incision knife mechanism, increasing the precision of surgical manipulation. The dural knife is driven by the driving mechanism to move back and forth to simulate the action of manual cutting, and the cutting depth of the dural knife can also be controlled, thereby further increasing the precision of dural incision, allowing for more effortless and convenient cutting.

This invention provides a novel target PDE4B for the prevention and treatment of Cryptococcus neoformans brain infection. Specifically, it relates to the application of drugs targeting phosphodiesterase PDE4B in the preparation of drugs for the prevention and / or treatment of Cryptococcus neoformans meningoencephalitis. The drug targeting PDE4B is the PDE4B agonist MR-L2 (CAS: 2374703-19-0). The PDE4B agonist MR-L2 described in this invention can significantly reduce Cryptococcus neoformans brain infection, providing an effective prevention and treatment method for Cryptococcus neoformans meningoencephalitis.

The utility model relates to medical instrument technical field discloses a kind of clamping position shunt and interventional medical instrument.The utility model includes a kind of clamping position shunt, is conveyed and is disposed in the ventricular system and venous system of patient by conveying system and exports cerebrospinal fluid in the ventricular system of patient to venous system, the dura mater between ventricular system and venous system is equipped with puncture hole, the puncture catheter with puncture needle head is included in conveying process, clamping position shunt is arranged in puncture catheter, the proximal end side wall of puncture needle head is equipped with at least one shunt tube installation slot, clamping position shunt includes the shunt tube body for being disposed in venous system and the distal end part for being disposed in ventricular system.The utility model is improved by clamping position shunt and its conveying system, not only simplifies conveying system structure, so that the operation of conveying system is more convenient, operation risk is lower, and shunt tube can also be provided with protection to puncture catheter.

A pharmaceutical composition, comprising panobinostat and tazemetostat. Combination of tazemetostat which is an EZH2 inhibitor with panobinostat, pembrolizumab and ipilimumab is clinically used for treating patients suffering from later-stage diffuse midline glioma, H3K27-altered, accompanied with leptomeningeal / pia mater spinalis spread, and patients suffering from primary, relapsing and progressing diffuse midline glioma, H3K27-altered. The pharmaceutical composition has remarkable curative effects, can obviously inhibit tumor growth, reduce the tumor volume, improve the life quality for patients, and prolong the survival time of patients.

The application relates to the field of interventional medical technology, in particular to a percutaneous interventional venous sinus puncture access device. The access device is formed by the mutual cooperation of a balloon catheter, a deflecting catheter and a puncture guide wire, can puncture into the subarachnoid cavity in the cranial cavity on the venous sinus without damaging the brain, break the dura mater and arachnoid, construct a stoma between the pontocerebellar angle pool and the inferior petrosal sinus, and make the cerebrospinal fluid flow from the subarachnoid cavity to the venous sinus, to the jugular vein and to the heart, and participate in blood circulation. The access device can also be used for delivering a shunt, so that the hydrocephalus which can only be effectively treated by operation in the past can be treated by a minimally invasive interventional method, the access device is not used for surgical open operation, the intraoperative trauma is reduced, the operation time is saved, and the possibility of postoperative infection is greatly reduced.

An RNAi agent and composition that inhibits expression of transthyretin (TTR) for use in the treatment and / or prevention of ATTR-associated diseases, including ATTR-PN (transthyretin amyloidosis polyneuropathy), ATTR-CM (transthyretin amyloidosis cardiomyopathy), senile systemic amyloidosis disease, leptomeningeal / central nervous system amyloidosis disease.

The invention relates to a system based on the anatomy of the middle meningeal artery, for simulating embolisation with embolic substances. The configuration of the system allows for quick assembly and disassembly, facilitating its use in training workshops. This improves the quality of medical training and promotes the use of this non-invasive treatment for chronic subdural haematomas. The invention comprises a base that acts as a support and stabiliser, and a branched model which, with internal diameters of up to 0.5 mm, replicates the actual internal anatomical tortuosity of the middle meningeal artery.

Surgical constructs, assemblies, kits and methods of tissue fixation are disclosed. A suture passing instrument includes a curved tip integral with a distal end of a shaft, a hand assembly mounted on a proximal end of the shaft, and a flexible strand attached to one or two needles and loaded through a cannulation of the shaft. The curve-shaped tip is adapted to engage dural tissue during repairs of the dura mater. The suture passing instrument can grasp and manipulate dura mater and can allow multiple suture passes through the dura mater without removal of the instrument from the durotomy site. The suture passing instrument is provided with a safety mechanism that prohibits the needle(s) to be fired into nerves, providing a safe, reliable, inexpensive, and speedy repair of a durotomy.

The application discloses a kind of risk stratification model construction method and system for EGFR mutant non-small cell lung cancer meningeal metastasis patient, belong to tumor prognosis evaluation technical field.The multicenter retrospective clinical database is first constructed and data preprocessing is completed, then the predictor is screened by LASSO Cox regression, and the five core prognostic factors of ECOG PS score, brain metastasis, MRI meningeal enhancement, CSFC result and intracranial pressure are determined by multi-factor Cox proportional risk regression and linear predictor is constructed, then it is converted into integer type weighted risk score, finally the best cutoff value is determined based on survival function, and the patient is divided into low-risk group and high-risk group.The application can clearly distinguish the patient group with significant difference in prognosis, the required indicators are all clinical routine items, the operation is simple, the accessibility is high, can accurately guide individualized treatment decision and clinical trial stratification, and has important clinical application value.

The invention provides application of propranolol or pharmaceutically acceptable salts thereof in preparation of drugs for inhibiting lung cancer meningeal metastasis. The invention discloses the application of blocking neuroendocrine differentiation in prevention and treatment of tumor meningeal metastasis for the first time, the neuroendocrine differentiation of lung cancer is blocked by propranolol, and the survival ability of lung cancer cells in a cerebrospinal fluid environment can be weakened, so that the lung cancer meningeal metastasis is inhibited, and the lung cancer is finally improved or treated. Neuroendocrine differentiation is found to be a key regulation factor of lung cancer meningeal metastasis, and potential development prospects are achieved by blocking lung cancer neuroendocrine differentiation through propranolol so as to inhibit lung cancer meningeal metastasis.